Sucher Joseph F, Barletta Jeffrey F, Shirah Gina R, Prokuski Laura J, Montanarella Paul D, Dzandu James K, Mangram Alicia J
HonorHealth Deer, Valley Hospital, United States.
Midwestern University, College of Pharmacy, United States.
Am J Surg. 2022 Dec;224(6):1473-1477. doi: 10.1016/j.amjsurg.2022.08.019. Epub 2022 Sep 7.
BACKGROUND: Fascia iliaca compartment block (FICB) is an effective method to treat pain in adult trauma patients with hip fracture. Of importance is the high prevalence of preinjury anticoagulants and antiplatelet medications in this population. To date, we have not identified any literature that has specifically evaluated the safety of FICB with continuous catheter infusion in patients on antiplatelet and/or anticoagulant therapy. The purpose of this study is to quantify the complication rate associated with FICB in patients who are actively taking prescribed anticoagulant and/or antiplatelet medications prior to injury and identify factors that may predispose patients to an adverse event. METHODS: This retrospective study included consecutive adult trauma patients (age ≥18) with hip fracture who underwent placement of FICB within 24 h of admission and had been taking anticoagulant and/or antiplatelet medications pre-injury. Patients were excluded if their catheter was placed more than 24 h post-hospital admission. Patients were evaluated for demographics, injury severity, laboratory values, medication history, receipt of coagulation-related reversal medications, and complications related to FICB placement. Complications included bleeding at the insertion site requiring catheter removal and 30-day catheter site infection. The incidence of complications was reported and risk factors for complications were identified using univariate and multivariate statistics. RESULTS: There were 124 patients included. The mean age was 81 ± 10 years, and the most common mechanism was ground level fall (94%). Most patients were taking single antiplatelet therapy (65%), followed by anticoagulant alone (21%), combined antiplatelet and anticoagulant therapy (7.3%) and dual antiplatelet therapy (7.3%). The most common antiplatelet was aspirin (88%) and the most common anticoagulant was warfarin (60%). Of the patients taking warfarin, the average INR on admission was 2.3 ± 0.8. Only 1 bleeding complication (0.8%) was noted in a patient prescribed clopidogrel pre-injury which occurred 5 days post-catheter placement. This same patient was noted to have superficial surgical site bleeding most likely secondary to the use of enoxaparin for post-operative deep venous thrombosis prophylaxis. There were 4 orthopedic superficial surgical site infections (3.2%), all remote from the catheter site. The pre-injury medication prescribed in these patients was aspirin 81 mg, aspirin 325 mg, rivaroxaban and dabigatran, respectively. No factors were associated with a complication thus multivariate analysis was not performed. CONCLUSION: The incidence of complications associated with fascia iliaca compartment block (FICB) in adult trauma patients prescribed pre-injury anticoagulants or antiplatelet medications is low. In this retrospective review, we did not identify any complications that were directly associated with the FICB procedure. Fascia iliaca block with continuous infusion catheter placement can be safely performed on patients who are on therapeutic anticoagulant and/or antiplatelet agents.
背景:髂筋膜间隙阻滞(FICB)是治疗成年髋部骨折创伤患者疼痛的有效方法。该人群中伤前使用抗凝剂和抗血小板药物的比例很高。迄今为止,我们尚未发现有文献专门评估在接受抗血小板和/或抗凝治疗的患者中持续导管输注FICB的安全性。本研究的目的是量化在伤前积极服用规定的抗凝剂和/或抗血小板药物的患者中与FICB相关的并发症发生率,并确定可能使患者易发生不良事件的因素。 方法:这项回顾性研究纳入了连续的成年创伤患者(年龄≥18岁),这些患者因髋部骨折在入院后24小时内接受了FICB置管,且伤前一直在服用抗凝剂和/或抗血小板药物。如果患者的导管在入院后超过24小时放置,则将其排除。对患者进行人口统计学、损伤严重程度、实验室检查值、用药史、凝血相关逆转药物的使用情况以及与FICB置管相关的并发症评估。并发症包括插入部位出血需要拔除导管以及30天导管部位感染。报告并发症的发生率,并使用单因素和多因素统计方法确定并发症的危险因素。 结果:共纳入124例患者。平均年龄为81±10岁,最常见的受伤机制是平地跌倒(94%)。大多数患者接受单一抗血小板治疗(65%),其次是单独使用抗凝剂(21%)、联合抗血小板和抗凝治疗(7.3%)以及双联抗血小板治疗(7.3%)。最常用的抗血小板药物是阿司匹林(88%),最常用的抗凝剂是华法林(60%)。在服用华法林的患者中,入院时平均国际标准化比值(INR)为2.3±0.8。仅1例伤前服用氯吡格雷的患者在置管后5天出现出血并发症(0.8%)。该患者还出现了手术部位浅表出血,很可能是由于使用依诺肝素预防术后深静脉血栓形成所致。有4例骨科手术部位浅表感染(3.2%),均远离导管部位。这些患者伤前服用的药物分别为81毫克阿司匹林、325毫克阿司匹林、利伐沙班和达比加群。没有因素与并发症相关,因此未进行多因素分析。 结论:在伤前服用抗凝剂或抗血小板药物的成年创伤患者中,与髂筋膜间隙阻滞(FICB)相关的并发症发生率较低。在这项回顾性研究中,我们未发现任何与FICB操作直接相关的并发症。对于正在接受治疗性抗凝和/或抗血小板药物治疗的患者,可以安全地进行带连续输注导管的髂筋膜阻滞。
Curr Pain Headache Rep. 2021-3-11